Pulse Biosciences, Inc. (NASDAQ:PLSE) Shares Purchased by Barclays PLC

Barclays PLC lifted its holdings in shares of Pulse Biosciences, Inc. (NASDAQ:PLSE - Free Report) by 361.4% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 30,306 shares of the company's stock after buying an additional 23,738 shares during the period. Barclays PLC's holdings in Pulse Biosciences were worth $530,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Rhumbline Advisers increased its stake in Pulse Biosciences by 6.7% in the 2nd quarter. Rhumbline Advisers now owns 25,729 shares of the company's stock valued at $288,000 after buying an additional 1,608 shares during the period. Creative Planning boosted its holdings in shares of Pulse Biosciences by 113.9% in the third quarter. Creative Planning now owns 21,910 shares of the company's stock valued at $384,000 after acquiring an additional 11,667 shares in the last quarter. Bank of New York Mellon Corp increased its stake in shares of Pulse Biosciences by 23.4% during the second quarter. Bank of New York Mellon Corp now owns 50,914 shares of the company's stock worth $570,000 after acquiring an additional 9,639 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new position in Pulse Biosciences during the third quarter worth about $588,000. Finally, Charles Schwab Investment Management Inc. lifted its position in Pulse Biosciences by 193.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 148,114 shares of the company's stock valued at $2,598,000 after purchasing an additional 97,565 shares during the period. Hedge funds and other institutional investors own 76.95% of the company's stock.

Analyst Upgrades and Downgrades

Separately, StockNews.com upgraded Pulse Biosciences to a "sell" rating in a research note on Thursday, January 2nd.

Insider Activity

In other news, CEO Burke Thomas Barrett sold 50,000 shares of the company's stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $17.42, for a total value of $871,000.00. Following the sale, the chief executive officer now directly owns 63,172 shares in the company, valued at $1,100,456.24. This represents a 44.18 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Robert W. Duggan acquired 56,054 shares of the company's stock in a transaction that occurred on Wednesday, December 11th. The shares were bought at an average price of $17.35 per share, with a total value of $972,536.90. Following the transaction, the director now owns 42,228,057 shares in the company, valued at $732,656,788.95. This represents a 0.13 % increase in their position. The disclosure for this purchase can be found here. Company insiders own 71.50% of the company's stock.

Pulse Biosciences Stock Performance

Shares of PLSE traded down $0.03 during trading hours on Friday, reaching $17.61. The company had a trading volume of 92,511 shares, compared to its average volume of 138,259. Pulse Biosciences, Inc. has a 12-month low of $6.59 and a 12-month high of $22.69. The firm has a 50 day simple moving average of $18.25 and a 200-day simple moving average of $17.50.

Pulse Biosciences (NASDAQ:PLSE - Get Free Report) last issued its earnings results on Wednesday, October 30th. The company reported ($0.21) earnings per share (EPS) for the quarter. During the same quarter in the prior year, the firm earned ($0.19) EPS.

Pulse Biosciences Profile

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.